Doesn’t look good for the insulin-bong:
“I think Pfizer will wish they had never gotten into this. I doubt they’ll regain their investment,” says Dr. John Buse, president-elect of the American Diabetes Association, who participated in Exubera’s trials. “There is no advantage to Exubera and there may be a safety risk. I see it as my job to talk people out of (using) it.”
